Fecal transplant for drug-resistant Klebsiella pneumonia
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests whether transplanting healthy donor stool into the lungs can help treat a severe pneumonia caused by a bacteria that is resistant to many antibiotics. It may offer a new option for people whose infection is not responding to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have pneumonia (either community-acquired or hospital-acquired).
- Lab tests confirm your pneumonia is caused by a drug-resistant Klebsiella pneumoniae bacteria.
- You are willing to provide sputum, lung fluid, and stool samples, and to receive the fecal transplant.
- You do not have severe lung disease, a weakened immune system, or active cancer that would make the procedure unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether putting healthy donor stool into the gut of people with sepsis can improve their recovery. It aims to see if this treatment helps reduce the chance of dying or getting worse in the ICU.
This trial studies fecal microbiota transplantation (a stool-based treatment) to improve symptoms and safety in people with certain gut and immune conditions. It aims to see whether changing gut bacteria can help you feel better.
This trial studies whether fecal microbiota transplantation (FMT)—a medical procedure using stool from a screened donor to restore gut bacteria—can improve safety and outcomes for people with certain bowel, immune, and metabolic conditions. It may help if your symptoms are thought to be related to an unhealthy gut microbiome, though eligibility is broad and depends on specific safety factors.
This Phase 3 study tests whether a fecal microbiota transplant (FMT) can eliminate hard-to-treat bacteria in the gut, such as ESBL or carbapenem-resistant bacteria. If it works, it may reduce future infections and antibiotic-resistant illness.
This trial tests whether transplanting healthy donor bacteria (fecal microbiota) into the gut can help adults with blood cancers who have stubborn infections, C. diff, or complications after stem cell transplant. It may reduce dangerous germs and improve gut health.
This study tests a stool-based treatment (fecal microbiota treatment) to help remove “carbapenem-resistant” bacteria living in the gut. If you carry these bacteria without being sick, the goal is to reduce or stop that colonization.
Hear when a new Klebsiella Pneumoniae Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.